🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT04968548
Active, not recruiting Observational

Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening

NCT04968548 · tracked via the Priya Life Science USA tracker
Sponsor
Nucleix Ltd.
Phase
Observational
Started
2021-09-17
Last updated
2025-11-04

Condition(s) studied

Lung Cancer

Investigational drug(s) / intervention(s)

Blood collection

Blood collection: Peripheral blood will be collected via routine venipuncture procedure

Study summary

This study is part of the development and validation of a non-invasive lung screening test which aim to identify early stage lung cancer in patients at high risk for lung cancer.

Eligibility

Sex
ALL
Min age
50 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria - Cases: * Current or past smokers, with at least 20 pack-years * Subjects with either A high suspicion for lung cancer, with planned surgery to establish a definitive diagnosis within 60 days after date of blood collection OR treatment naive lung cancer patients Exclusion Criteria - Cases: * Known diagnosis or treatment of any previous cancer, including lung cancer, in the past 5 years, except for fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix * Current lung cancer is known to be stage III or IV by pathology. Inclusion Criteria - Screening: \- Current or past smokers, with at least 20 pack-years, undergoing LDCT for lung cancer screening Exclusion Criteria - Screening: * Known diagnosis or treatment of any cancer, including lung cancer, in the past 5 years, except for fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix * Subjects whose purpose of performing LDCT is for surveillance of a lung nodule

Primary outcome measure(s)

Trial sites (31)

FacilityCityRegionStatus
Scripps Memorial Hospital Encinitas California
Centura Health Lakewood Colorado
VA Connecticut Healthcare System West Haven Connecticut
Orlando Health, Inc. Orlando Florida
Sarasota Memorial Hospital Sarasota Florida
St. Elizabeth Edgewood Hospital Edgewood Kentucky
Norton Cancer Institute Louisville Kentucky
Owensboro Health Owensboro Kentucky
Johns Hopkins Medical Center Baltimore Maryland
Lahey Hospital and Medical Center Burlington Massachusetts
University of Minnesota Health Minneapolis Minnesota
Harry S. Truman Memorial Veterans' Hospital Columbia Missouri
Washington University in St. Louis St Louis Missouri
Northwell Health New Hyde Park New York
University of Rochester Rochester New York
The University of North Carolina Chapel Hill North Carolina
Duke University Durham North Carolina
Durham VA Health Care System Durham North Carolina
W.G. (Bill) Hefner VA Medical Center Salisbury North Carolina
Novant Health Cancer Research Winston-Salem North Carolina
Summa Health Akron Ohio
Cleveland Clinic Foundation Cleveland Ohio
Thomas Jefferson University Philadelphia Pennsylvania
Ralph H. Johnson VA Medical Center Charleston South Carolina
Medical University of South Carolina (MUSC) Charleston South Carolina
Baptist Cancer Center Memphis Tennessee
Michael E. DeBakey VA Medical Center Houston Texas
University of Calgary Calgary Alberta
Vancouver General Hospital/The University of British Columbia Vancouver British Columbia
University Health Network Toronto Ontario
McGill University Health Centre Montreal Quebec

More Nucleix Ltd. trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04968548 on ClinicalTrials.gov ↗ ← All trials in the USA